Do established biomarkers such as B-type natriuretic peptide and troponin predict rejection?

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose of review: Acute cardiac allograft rejection surveillance has historically been based on serial endomyocardial biopsy (EMB). Limitations with this approach have stimulated interest in identifying noninvasive surrogate markers of rejection. This review summarizes the evidence assessing the use of direct cardiac markers B-type natriuretic peptide (BNP) and cardiac troponins in detecting acute allograft rejection. Recent findings: BNP, its amino-terminal fragment NT-proBNP, and cardiac troponins T and I have all been extensively evaluated for this purpose, and so far have demonstrated inadequate diagnostic accuracy to replace EMB. Longitudinal surveillance of BNP and NT-proBNP appears to offer promise for improved accuracy, but has not been adequately evaluated in prospective studies. Preliminary investigations into highly sensitive troponin assays suggest a potential role in rejection surveillance, but prospective validation in larger studies is needed. Summary: EMB remains the gold standard for cardiac allograft rejection surveillance. However, recent data indicate potential clinical utility for serial monitoring of natriuretic peptides. If further investigation into highly sensitive troponin assays confirms the positive data so far reported, further efforts directed toward a longitudinal-based rejection surveillance algorithm incorporating both troponin and BNP may identify a strategy that could serve as an alternative to EMB.

Original languageEnglish (US)
Pages (from-to)581-588
Number of pages8
JournalCurrent Opinion in Organ Transplantation
Volume18
Issue number5
DOIs
StatePublished - Oct 2013

Fingerprint

Troponin
Brain Natriuretic Peptide
Biomarkers
Allografts
Biopsy
Natriuretic Peptides
Troponin T
Troponin I
Prospective Studies
pro-brain natriuretic peptide (1-76)

Keywords

  • Acute allograft rejection
  • B-type natriuretic peptide
  • Heart transplantation
  • Highly sensitive troponin

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation

Cite this

Do established biomarkers such as B-type natriuretic peptide and troponin predict rejection? / Hill, Douglas A.; Drazner, Mark H; de Lemos, James A.

In: Current Opinion in Organ Transplantation, Vol. 18, No. 5, 10.2013, p. 581-588.

Research output: Contribution to journalArticle

@article{8d088c05b7bb411a9433269335d06865,
title = "Do established biomarkers such as B-type natriuretic peptide and troponin predict rejection?",
abstract = "Purpose of review: Acute cardiac allograft rejection surveillance has historically been based on serial endomyocardial biopsy (EMB). Limitations with this approach have stimulated interest in identifying noninvasive surrogate markers of rejection. This review summarizes the evidence assessing the use of direct cardiac markers B-type natriuretic peptide (BNP) and cardiac troponins in detecting acute allograft rejection. Recent findings: BNP, its amino-terminal fragment NT-proBNP, and cardiac troponins T and I have all been extensively evaluated for this purpose, and so far have demonstrated inadequate diagnostic accuracy to replace EMB. Longitudinal surveillance of BNP and NT-proBNP appears to offer promise for improved accuracy, but has not been adequately evaluated in prospective studies. Preliminary investigations into highly sensitive troponin assays suggest a potential role in rejection surveillance, but prospective validation in larger studies is needed. Summary: EMB remains the gold standard for cardiac allograft rejection surveillance. However, recent data indicate potential clinical utility for serial monitoring of natriuretic peptides. If further investigation into highly sensitive troponin assays confirms the positive data so far reported, further efforts directed toward a longitudinal-based rejection surveillance algorithm incorporating both troponin and BNP may identify a strategy that could serve as an alternative to EMB.",
keywords = "Acute allograft rejection, B-type natriuretic peptide, Heart transplantation, Highly sensitive troponin",
author = "Hill, {Douglas A.} and Drazner, {Mark H} and {de Lemos}, {James A}",
year = "2013",
month = "10",
doi = "10.1097/MOT.0b013e328364fe23",
language = "English (US)",
volume = "18",
pages = "581--588",
journal = "Current Opinion in Organ Transplantation",
issn = "1087-2418",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Do established biomarkers such as B-type natriuretic peptide and troponin predict rejection?

AU - Hill, Douglas A.

AU - Drazner, Mark H

AU - de Lemos, James A

PY - 2013/10

Y1 - 2013/10

N2 - Purpose of review: Acute cardiac allograft rejection surveillance has historically been based on serial endomyocardial biopsy (EMB). Limitations with this approach have stimulated interest in identifying noninvasive surrogate markers of rejection. This review summarizes the evidence assessing the use of direct cardiac markers B-type natriuretic peptide (BNP) and cardiac troponins in detecting acute allograft rejection. Recent findings: BNP, its amino-terminal fragment NT-proBNP, and cardiac troponins T and I have all been extensively evaluated for this purpose, and so far have demonstrated inadequate diagnostic accuracy to replace EMB. Longitudinal surveillance of BNP and NT-proBNP appears to offer promise for improved accuracy, but has not been adequately evaluated in prospective studies. Preliminary investigations into highly sensitive troponin assays suggest a potential role in rejection surveillance, but prospective validation in larger studies is needed. Summary: EMB remains the gold standard for cardiac allograft rejection surveillance. However, recent data indicate potential clinical utility for serial monitoring of natriuretic peptides. If further investigation into highly sensitive troponin assays confirms the positive data so far reported, further efforts directed toward a longitudinal-based rejection surveillance algorithm incorporating both troponin and BNP may identify a strategy that could serve as an alternative to EMB.

AB - Purpose of review: Acute cardiac allograft rejection surveillance has historically been based on serial endomyocardial biopsy (EMB). Limitations with this approach have stimulated interest in identifying noninvasive surrogate markers of rejection. This review summarizes the evidence assessing the use of direct cardiac markers B-type natriuretic peptide (BNP) and cardiac troponins in detecting acute allograft rejection. Recent findings: BNP, its amino-terminal fragment NT-proBNP, and cardiac troponins T and I have all been extensively evaluated for this purpose, and so far have demonstrated inadequate diagnostic accuracy to replace EMB. Longitudinal surveillance of BNP and NT-proBNP appears to offer promise for improved accuracy, but has not been adequately evaluated in prospective studies. Preliminary investigations into highly sensitive troponin assays suggest a potential role in rejection surveillance, but prospective validation in larger studies is needed. Summary: EMB remains the gold standard for cardiac allograft rejection surveillance. However, recent data indicate potential clinical utility for serial monitoring of natriuretic peptides. If further investigation into highly sensitive troponin assays confirms the positive data so far reported, further efforts directed toward a longitudinal-based rejection surveillance algorithm incorporating both troponin and BNP may identify a strategy that could serve as an alternative to EMB.

KW - Acute allograft rejection

KW - B-type natriuretic peptide

KW - Heart transplantation

KW - Highly sensitive troponin

UR - http://www.scopus.com/inward/record.url?scp=84888293483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888293483&partnerID=8YFLogxK

U2 - 10.1097/MOT.0b013e328364fe23

DO - 10.1097/MOT.0b013e328364fe23

M3 - Article

C2 - 23995368

AN - SCOPUS:84888293483

VL - 18

SP - 581

EP - 588

JO - Current Opinion in Organ Transplantation

JF - Current Opinion in Organ Transplantation

SN - 1087-2418

IS - 5

ER -